Antithrombin Market|Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A,

 

Antithrombin is a blood protein that prevents blood clotting by inactivating the enzyme thrombin. Antithrombin is a 432 amino acid protein generated by the liver. Acquired antithrombin deficiency, which is caused by various disorders such nephrotic syndrome, liver failure, severe trauma, and metastatic cancers, and hereditary antithrombin deficiency, which is caused by a genetic mutation or aberration, are the two main causes of antithrombin deficiency. Inherited antithrombin deficiency is a rare condition, with about 0.2 percent of the global population suffering from it, according to the NCBI (National Center for Biotechnology Information).

ATryn, which was created by rEVO Biologics and acquired the U.S. Food and Drug Administration's approval, is one of the most popular antithrombin deficiency medications on the market. In 2009, the Food and Drug Administration (FDA) granted approval. Antithrombin and heparin have a synergistic effect, enhancing antithrombin binding to Thrombin (factor II a) and Factor Xa. The antithrombin III blood test is used to determine how much antithrombin deficiency is causing the blood to clot more easily than usual.

Antithrombin market growth is aided by rising rates of coagulation disorders, open heart surgeries, and extracorporeal circulation during hemodialysis. According to the Centers for Disease Control and Prevention (CDC), venous thromboembolism affects roughly 900,000 persons in the United States each year. Furthermore, 5 to 8 percent of the U.S. population has an increased risk of suffering from thrombosis due to one of the several genetic risk factors known as inherited thrombophilia.

The global antithrombin market is divided into five regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Because of the acceptance of strong established technologies and antithrombin therapies, as well as high awareness and rising regulatory approval of medications in these regions, North America is likely to gain substantial traction in the global antithrombin market, followed by Europe..

There are only a few well-established players in the antithrombin market. Because these few competitors control such a large portion of the market, there is fierce competition. Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, Scripps Laboratories Inc., GTC Biotherapeutics, Inc.'s, Green Cross Corp., and BDI Pharma are some of the major companies in the worldwide antithrombin industry.